ArticleBiochemical and biophysical research communications2011
Integrin αβ1, αvβ, α6β effectors p130Cas, Src and talin regulate carcinoma invasion and chemoresistance.
Article in Biochemical and biophysical research communications, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Drug resistance‑related gene targets and molecular mechanisms in the A2780/Taxol‑resistant epithelial ovarian cancer cell line.Oncology letters · 2024Article
- Fibroblasts as Turned Agents in Cancer Progression.Cancers · 2023Review
- P130cas-FAK interaction is essential for YAP-mediated radioresistance of non-small cell lung cancer.Cell death & disease · 2022Article
- Prognostic value of Talin-1 in renal cell carcinoma and its association with B7-H3.Cancer biomarkers : section A of Disease markers · 2022Article
- Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and β1 integrin activation.Oncogene · 2020Article
- Decellularized Extracellular Matrix for Cancer Research.Materials (Basel, Switzerland) · 2019Review
- Platelet protein biomarker panel for ovarian cancer diagnosis.Biomarker research · 2018Article
- Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression.Convergent science physical oncology · 2017Article
- Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling.Oncotarget · 2016Article
- miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics.Molecular cancer research : MCR · 2016Article
- Mechanisms of Invasion in Head and Neck Cancer.Archives of pathology & laboratory medicine · 2015Review
- Dissecting the Potential Interplay of DEK Functions in Inflammation and Cancer.Journal of oncology · 2015Review
- Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma.PloS one · 2015Article
- Concise review: role of DEK in stem/progenitor cell biology.Stem cells (Dayton, Ohio) · 2013Review
- A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B-cell lymphoma with central nervous system involvement.Haematologica · 2013Article
- Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells.Journal of proteome research · 2013Article
- ErbB/integrin signaling interactions in regulation of myocardial cell-cell and cell-matrix interactions.Biochimica et biophysica acta · 2013Review
- Quantum dots for cancer research: current status, remaining issues, and future perspectives.Cancer biology & medicine · 2012Article
- Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.EMBO molecular medicine · 2012Review
- Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Ligand engagement by integrins induces receptor clustering and formation of complexes at the integrin cytoplasmic face that controls cell signaling and cytoskeletal dynamics critical for adhesion-dependent processes. This study searches for a subset of integrin effectors that coordinates both tumor cell invasion and resistance to the chemotherapeutic drug cisplatin in oral carcinomas. Candidate integrin effectors were identified in a proteomics screen of proteins recruited to clustered integrin αβ1, α(v)β or α(6)β receptors in oral carcinomas. Proteins with diverse functions including microtubule and actin binding proteins, and factors involved in trafficking, transcription and translation were identified in oral carcinoma integrin complexes. Knockdown of effectors in the oral carcinoma HN12 cells revealed that p130Cas, Dek, Src and talin were required for invasion through Matrigel. Disruption of talin or p130Cas by RNA interference increased resistance to cisplatin, whereas targeting Dek, Src or zyxin reduced HN12 resistance to cisplatin. Analysis of the spreading of HN12 cells on collagen I and laminin I revealed that a decrease in p130Cas or talin expression inhibited spreading on both matrices. Interestingly, a reduction in zyxin expression enhanced spreading on laminin I and inhibited spreading on collagen I. Reduction of Dek, Src, talin or zyxin expression reduced HN12 proliferation by 30%. Proliferation was not affected by a reduction in p130Cas expression. We conclude that p130Cas, Src and talin function in both oral carcinoma invasion and resistance to cisplatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.